AYA.AX stock A$3.27 pre-market 07 Feb 2026: AI diagnostics growth remains the core insight

AYA.AX stock trades at A$3.27 in ASX pre-market on 07 Feb 2026, down -3.25% from yesterday. This move follows a short-term pullback from a 52-week high of A$5.24 and sits above the 200-day average of A$2.34. Investors focused on AI in healthcare should note Artrya Limited reports EPS -0.17 and a market cap near A$370556400.00. We use price, volumes and sector context to link recent trading to growth forecasts and the upcoming earnings date on 24 Feb 2026.

AYA.AX stock: Key market data and session context

AYA.AX stock opened at A$3.23 and shows a day range A$3.06–A$3.30. Volume is 548773.00 versus an average of 766167.00, signalling lighter pre-market flow. The share count is 113320000.00 and market cap is A$370556400.00. These metrics explain why price moves amplify on news in the AI healthcare niche. Recent price history and trading details are available on Investing.com.

AYA.AX stock: Financials and valuation snapshot

Artrya reports EPS -0.17 and a PE ratio of -19.24, reflecting current losses as it scales. Price to book is 16.36 and cash per share is 0.11. The firm shows a strong current ratio near 8.27 and minimal debt to equity at 0.03. Those ratios signal liquidity but high valuation multiples versus revenue. For long-term investors, growth must justify these multiples.

AYA.AX stock: Technicals and trading setup

Technically AYA.AX stock is in a strong short-term trend. RSI reads 70.89 and ADX is 40.86, indicating momentum and a strong trend. Bollinger lower band sits at 3.23 and middle at 4.20, so current price is below the mid band. On balance volume shows accumulation, while ATR is 0.32, implying measured volatility. Traders should watch a break above A$4.04 50-day average or a drop to A$2.34 200-day support.

AYA.AX stock: Analyst signals and Meyka grade

Meyka AI rates AYA.AX with a score out of 100. Score: 63.21 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating database shows mixed ratio scores but highlights strong liquidity and AI-driven opportunity in diagnostics. Grades are model outputs and not financial advice.

AYA.AX stock: Risks and opportunities for AI healthcare investors

Artrya’s Salix AI product is a clear growth opportunity in coronary disease detection, which supports upside if clinical adoption rises. Risks include negative earnings, high R&D spend, and steep valuation versus revenue. Key operational risks are receivables efficiency and cash burn. Regulatory and hospital procurement cycles can also slow revenue recognition. Investors should weigh adoption milestones against cash runway metrics.

AYA.AX stock: Price targets and forecast outlook

Meyka AI’s forecast model projects monthly A$3.56, quarterly A$5.83, and yearly A$7.90 for AYA.AX stock. Versus the current A$3.27, the 12-month target implies 141.56% upside. We present a pragmatic range: short-term price target A$3.80, base 12-month target A$7.90, and a conservative downside case A$2.00. Forecasts are model-based projections and not guarantees.

Final Thoughts

AYA.AX stock trades at A$3.27 pre-market on 07 Feb 2026 amid mixed momentum and strong sector interest in AI diagnostics. Fundamental ratios show heavy investment and current losses, with EPS -0.17 and PE -19.24. Technicals show short-term strength with RSI 70.89 and ADX 40.86, but price sits under the 50-day average A$4.04, a level to clear for renewed buyers. Meyka AI’s forecast model projects a 12-month price of A$7.90, implying 141.56% upside from today. Our Meyka grade is B (63.21) with a HOLD suggestion, reflecting a balance of growth potential and execution risk. Watch the earnings update on 24 Feb 2026 for adoption signals and revenue guidance. For more real-time data use Meyka AI’s platform and the Artrya ASX page to track updates and trading flows. Forecasts are model projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.